The ATP-binding cassette (ABC) transporters constitute a family of large membrane proteins, which transport a variety of substrates across membranes. The ABCA4 protein is expressed in photoreceptors and possibly functions as a transporter for N-retinylidene-phosphatidylethanolamine (N-retinylidene-PE), the Schiff base adduct of all-trans-retinal with PE. Mutations in the ABCA4 gene have been initially associated with autosomal recessive Stargardt disease. Subsequent studies have shown that mutations in ABCA4 can also cause a variety of other retinal dystrophies including cone rod dystrophy and retinitis pigmentosa. To determine the prevalence and mutation spectrum of ABCA4 gene mutations in non-Stargardt phenotypes, we have screened 64 unrelated patients with autosomal recessive cone (arCD) and cone rod dystrophy (arCRD) applying the Asper Ophthalmics ABCR400 microarray followed by DNA sequencing of all coding exons of the ABCA4 gene in subjects with single heterozygous mutations. Disease-associated ABCA4 alleles were identified in 20 of 64 patients with arCD or arCRD. In four of 64 patients (6%) only one mutant ABCA4 allele was detected and in 16 patients (25%), mutations on both ABCA4 alleles were identified. Based on these data we estimate a prevalence of 31% for ABCA4 mutations in arCD and arCRD, supporting the concept that the ABCA4 gene is a major locus for various types of degenerative retinal diseases with abnormalities in cone or both cone and rod function.
Introduction
The ATP-binding cassette (ABC) transporters constitute a family of large membrane proteins which transport a variety of substrates across membranes. 1 One member of the family, the ABCA4 protein, is expressed in cone and rod photoreceptors 2 and possibly functions as a transporter for N-retinylidene-phosphatidylethanolamine (N-retinylidene-PE), the Schiff base adduct of all-trans-retinal with PE. 3 It has been proposed that a failure in the transport of alltrans-retinal from the luminal to the cytosolic side of photoreceptor discs may disrupt the visual cycle. Finally, it may lead to accumulation of N-retinylidene-PE and toxic lipofuscin A2-E in the RPE upon phagocytosis of photoreceptors.
ABCA4 gene mutations have been initially identified in patients with autosomal recessively inherited Stargardt disease and fundus flavimaculatus (both OMIM ID 248200) 4, 5 and subsequently also in autosomal recessively inherited cone rod dystrophy (arCRD, OMIM ID 604116) 6 and retinitis pigmentosa (OMIM ID 601718). 6 -8 Moreover, single heterozygous ABCA4 sequence variants have been proposed as a susceptibility factor for age-related macular degeneration (OMIM ID 153800). 9 Consequently, a genotype -phenotype correlation based on the residual function of the ABCA4 protein has been suggested. 10 Mutations in ABCA4 are the principal cause of Stargardt disease. However, predictions of the prevalence of ABCA4 gene mutations in arCRD have varied considerably between studies, ranging from 23 to 65%. 11 -14 Moreover, it has not yet been investigated whether ABCA4 mutation may also be involved in autosomal recessive cone dystrophy (arCD) with no detectable impairment of the rod system. To address these questions we investigated the prevalence of ABCA4 gene mutations in a large and clinically well-defined group of patients affected by arCD or arCRD.
Methods

Mutation analysis
Patients diagnosed with CD or CRD and a family history consistent with an autosomal recessive mode of inheritance were included in the study and recruited in four different centers (Centre for Ophthalmology, University Tübingen, Tübingen, Germany; Scheie Eye Institute, Department of Ophthalmology, University of Pennsylvania, Philadelphia, USA; Department of Ophthalmology, Charité Campus Benjamin Franklin, Berlin, Germany; Department of Ophthalmology, Ludwig Maximilians University, Munich, Germany). The study was performed according to the tenets of the Declaration of Helsinki and approved by the ethical committees of the participating institutions. Informed consent was obtained from all patients. Sixty-four patients met the inclusion criteria, 46 patients had arCRD, 18 patients had arCD. All patients were subsequently screened for ABCA4 gene mutations. The initial mutation screening was performed with the 10th version of the ABCR400 microarray (AsperBiotech, Tartu, Estonia) which queries 4450 known sequence variants (Supplementary Table 1 ). The genotyping procedure included PCR amplification of all ABCA4 exons, fragmentation of amplification products, and solid-phase mini-sequencing, also termed arrayed primer extension technology (APEX), which has been described in detail elsewhere. 15 Mutations identified by microarray genotyping were confirmed by conventional DNA sequencing of the relevant exon(s Genotypes for all patients with one or two diseaseassociated alleles are given in Table 1 . In total, microarray and the 'all-exon-sequencing' approach together identified 36 mutant ABCA4 alleles in 64 patients, representing 24 different sequence variants, including the complex allele (c.1622T4C;c.3113C4T) ( Table 2 ).
In our study group, missense mutations were most prevalent (17 of 37 mutations; 46%), followed by intronic and splice site mutations (12/37; 32%), nonsense mutations (4/37; 11%), and small deletions (4/37; 11%). Most sequence variants appeared only once. In contrast, the c.5461À10T4C allele was found in eight patients and thus was the most prevalent sequence variant in this study.
The ABCA4 gene mutation prevalence was higher in arCRD (16/46, 35%) than in arCD (4/18, 22%).
Classification of newly identified sequence alterations
Based on our 'all-exon-sequencing' strategy in subjects in whom only a single heterozygous mutation was detected by DNA chip analysis we identified three new sequence alterations that most likely represent disease-causing mutations. Two of the sequence variants are predicted to result in a truncated ABCA4 protein: c.700C4T constitutes an early stop mutation (p.Q234X), while the c.3539_3554del deletion leads to a frameshift and subsequent introduction of a premature termination codon after eight altered amino acid residues (p.S1181PfsX8). Furthermore, we observed a concordant segregation of c.3539_3554del in family ZD291 (Figure 1 ). The third novel sequence alteration c.4848 þ 2T4C affects the canonical GT-dinucleotide of the donor splice site of intron 34 and thus most likely impairs splicing of mutant transcripts. In addition, this sequence variant was not found in 246 chromosomes of healthy control individuals.
Segregation analysis in families affected by arCD and arCRD
We performed segregation analysis in all families in which samples from additional family members were available ( Figure 1 ). For an autosomal recessive mode of inheritance homozygous or compound heterozygous mutations in affected patients, and single heterozygous or no mutations in unaffected relatives is required, which we will call concordant segregation. Furthermore, independent segregation of mutations in trans (in subjects carrying two heterozygous mutations) is needed. A number of complex alleles (ie two sequence variants in cis) has been described in ABCA4. 27, 28 In total, independent and concordant segregation of the two mutations on different alleles could be demonstrated in nine families: RCD79, ZD289, RCD9, ZD291, ZD85, ZD290, RCD113, RCD337, RCD143. Three families did not fulfill all of the above stated segregation criteria. In family RCD 157 both affected siblings were concordant in being heterozygous for two mutations but we could not prove independent segregation because no other family members were available for segregation analysis. Only one single heterozygous sequence variant was identified during screening of the index patient in RCD63 and could be followed in that family. However, the presence of this mutation in all three affected siblings at least supports a causal relationship with the ABCA4 locus in this family. Pedigree RCD141 involves the marriage of two affected subjects (II:2 and II:3) and affected offspring. For II:3 concordant and independent segregation of two identified mutations can be demonstrated. The second ABCA4 mutation in the pedigree remains unidentified. Yet the segregation pattern is fully compatible with an autosomal recessive inheritance and linkage with the ABCA4 locus.
Clinical description of patients with arCD and arCRD and ABCA4 gene mutations The clinical data of the 20 index patients with at least one identified ABCA4 gene mutation were evaluated in detail (Table 3) . Most patients had arCRD (16/20) . Four patients had arCD, one of those with a differential diagnosis of arCRD. For both disease groups together, arCD and arCRD, the median age of onset was 9 years (range: 2 -27 years) and the mean visual acuity was 0. 
Discussion
Prevalence of ABCA4 gene mutations in arCRD and arCD In this study we evaluated the prevalence and spectrum of ABCA4 gene mutations in 64 patients affected by arCD and arCRD, using a microarray-based approach and subsequent 'all-exon-sequencing'. To our knowledge this is the largest number of arCD and arCRD patients assessed by a microarray-based ABCA4 mutation screening and the first time that ABCA4 gene mutations have been identified to cause arCD.
The reported prevalence of ABCA4 gene mutations in patients affected by arCRD varies among different studies, ranging from one fourth to almost two thirds of the studied populations. 11,12,14,29 -31 A recent investigation which combined previously published data with their own data calculated that ABCA4 gene mutations are found in 40% of the arCRD patients. 13 Our findings are consistent with previous reports as we identified ABCA4 gene mutations in 31% of our cohort. The different prevalences observed between studies might be attributed to ascertainment bias due to the relatively small sample sizes in previous reports, ranging from eight to 54 patients. The careful ascertainment of patients is also an important issue for exact determination of ABCA4 gene mutation prevalence in arCRD, since inclusion of patients with Stargardt disease, a phenotype with a relatively high ABCA4 gene mutation prevalence of 58 -75%, 23, 27 or arRP with an ABCA4 gene mutation prevalence of around 5%, 13 will bias the result.
In the current study, we performed the 'all-exonsequencing' only in selected patients who already had one identified mutant allele after microarray analysis. Thus, the actual prevalence of ABCA4 mutations in patients with arCD and arCRD could be higher. We also cannot exclude that we might have missed genomic rearrangement mutations based on the applied methods. Figure 1 Pedigrees of arCD and arCRD families segregating ABCA4 gene mutations. Index patients used for the ABCA4 microarray screening and subsequent DNA sequencing are marked by an arrow. Genotypes of all available family members are listed below the respective subject. A suspected but not identified second mutation in the ABCA4 gene is indicated with a question mark. Pedigrees are arranged from left to right and top to bottom in the same order as patients are listed in Table 1 . The pedigree number is given above left to each pedigree. Taken together, the ABCR400 microarray is rapid, costeffective and useful both in genetic diagnostics and research as a first screening tool.
ABCA4 gene analysis
The c.5461À10T4C mutation was the most common sequence variant in our patient sample, present both in patients with adCD and adCRD. It has been questioned whether this sequence variant is pathogenic on its own because heterologous expression of this mutation failed to show a splicing defect. 27 Therefore it has been suggested that the c.5461À10T4C is in linkage disequilibrium with another yet unknown pathogenic mutation. We found that six of eight patients carrying the c.5461À10T4C variant were also heterozygous for known pathogenic ABCA4 mutations, a much higher number than expected by chance.
Grading of ABCA4 mutations
A model which correlates phenotypes of retinal diseases with the residual activity of the mutant ABCA4 protein has been suggested. 10 Depending on a frequent founder mutation, c.2588G4C, which has been assumed to be mild, a model has been proposed that categorises mutations as null, moderately severe, or mild. A combination of two null mutations should lead to retinitis pigmentosa, whereas a combination of a null and a moderately severe mutation should cause CRD. Our data, however, do not support such a clear-cut genotype -phenotype correlation. For example, two of our arCRD patients (RCD79/6184 and RCD113/3668) are homozygous for putative null alleles (p.Y245X and p.V1973X). Another arCRD patient (RCD9/ 1989) harbours two mutations (p.P1380L and p.R2077W) which are both characterised by substantially impaired ATP-binding. 32 A fourth arCRD patient (RCD92/6809) is homozygous for the missense mutation p.L244P. Interestingly, a patient who is also a homozygote for p.L244P, but suffers from Stargardt disease has been described in the literature. 23 Moreover, there is no higher proportion of nonsense or truncating mutations in our sample of CRD and CD patients compared with that of a cohort comprised of Stargardt patients only. 27 Yet, we noted that certain mutations which are highly prevalent in Stargardt patients (recruited from a comparable population), 27 for example, the c.5882G4A, the c.3113C4T, and c.2588G4C mutations were rare in our sample; in contrast, the c.5461À10T4C variant is less common in Stargardt patients. Thus, although the model is attractive, it may not accurately predict the expression of the retinal disease. It has become clear in recent years that not only complex but also Mendelian diseases are shaped by modifying genetic or environmental factors. 33, 34 A model which includes the effect of modifying factors may increase understanding of the connection between genotype (at potentially various genetic loci), environment, and phenotype. Patients are listed from top to bottom in the same order as in Table 1 .
a All visual field defects include central scotomas if not stated. ID, identification number; Dis. dur., disease duration (years); BCVA, best corrected Snellen visual acuity; OD, right eye; OS, left eye; RPE, retinal pigment epithelium; GF-ERG, full field electroretinography; DD, differential diagnosis; M, macula; P, peripheral retina; C, central retina; qualitative measures of BCVA: CF, counting fingers; HM, perceiving hand movements; LP, correct indication of light projection; NI, no information.
In conclusion, we performed mutation analyses and provided data on the prevalence of ABCA4 gene mutations in patients with arCD and arCRD. Our data confirm and extend previous investigations that identified the ABCA4 gene as the major locus responsible for autosomal recessive retinal dystrophies, including arCD and arCRD.
